Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
By P. Armand, Haesook T. Kim, Brent R. Logan, Zhiwei Wang, E. Alyea, M. Kalaycio, R. Maziarz, J. Antin, R. Soiffer, D. Weisdorf and 3 more. Blood, 2014
883 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/51f13de97da92ee9fff2e22829827483b1d2a04b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. (2015, neutral): “2011-2012 79 (76%) 667 (53%) Follow up, median (range), mo 30 (7-59) 36 (9 -64)”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, methodology): “A Disease Risk Index based on disease stage and cytogenetics has been developed that predicts the likelihood of disease recurrence following myeloablative or RIC regimens, independent of age, conditioning intensity, graft source, and donor type.(191) The modified European Society for Blood and Marro”